Rosiglitazone (RGZ) inhibited the growth of ACC cells, activating the AMPK pathway, resulting in cellular vacuolization and enhanced autophagy. RGZ treatment also induced upregulation of Beclin-1 and LAMP-1. Here, LAMP1 is linked to adrenal cortex carcinoma.